Menu
Log in
Forgot password



Your Resource for Neurotherapeutics Discovery and Development


Log in
  • Home
  • Annual Meeting

Annual Meeting Overview

BECOME A SUPPORTER DOWNLOAD THE ADVANCE PROGRAM SUBMIT A LATE BREAKING ABSTRACT REGISTER TO ATTEND

BOOK YOUR HOTEL ROOM

Join us as the American Society for Experimental Neurotherapeutics Annual Meeting (ASENT 2025) will be held at Hyatt Regency Bethesda, in Bethesda, MD from March 12-14, 2025. 

ASENT's 2025 Annual Meeting is the premier neuroscience and neurotherapeutics conference where senior leaders from healthcare payers, providers and prescribers, employers, investors, fast-growing startups, big pharma, policymakers, funders and innovation centers gather to improve the process of bringing neurotherapeutics to market.

The Meeting features 12 symposia, which address therapeutic advances in a broad range neurologic disease states, processes and delivery methods; as well as interactive poster presentations, ASENT's celebrated pipeline presentations, and live discussion with speakers at the end of each day. 

2025 Meeting Highlights 

    • 12 - 16 Scientific Symposia featuring Neuroscience leaders from Industry, Academia, FDA, NIH, and Advocacy
    • DEBATE: Featuring a hot topic and current data
    • CNS PIPELINE Presentations
    • CAREER DINNER Featuring Guest Speakers
    • Interactive Poster Discussions
    • Sponsored Symposia from Innovation Leaders
    • Live Discussions in Breakout Rooms with Speakers
    • 2nd Annual Neurotherapeutics Clinical Trial Course - LIVE  (application only)


    This year our program will include symposia on:

    • Gene targeted therapy for Epilepsy
    • Universal Framework for Staging of Neurodegenerative Diseases
    • A Broader Look at Patient Focused Drug Development
    • Immunotherapy of Neurodegenerative Disorders
    • An Update on Pediatric Neurotherapeutics
    • Novel Therapies in Duchenne and Becker’s Muscular Dystrophy
    • Global Neuroinfectious Disease
    • Autoimmune Therapeutics presented inconjunction with the Japanese Society of Neurological Therapeutics
    • Diversity and Equity in Clinical Trials
    • ”Tell me about it” speech analysis in Neurodegenerative Diseases
    • Update on Pain Therapeutic Opportunities
    • Updates in Neurovascular and Stroke Therapeutics
    • Interactive Poster Discussions
    • Dynamic Pipeline Presentations
    • Live Discussions in Breakout Rooms with Speakers
    • And much, much more!


    Meeting Location

    Hyatt Regency Bethesda, Bethesda MD

    BOOK YOUR ROOM


    Who Attends

    50% of attendees are practicing physicians| Physician-Scientists | Neurologists | Neuroscientists | Drug and Device Companies | Fellows | Post-docs | Founders | Funders | Industry Leaders | Nonprofit Organizations and Advocacy Groups | Journal Editors | Representatives from NIH, NIA, NIDA, NINDS and FDA

    The 2025 meeting will feature a high number of junior faculty and trainees as attendees at our clinical trials course and neurotherapeutic drug discovery course are welcome to attend the annual meeting at a discounted cost. 

    Neurology students and residents interested in neurotherapeutic development will benefit from the insight of senior investigators and leaders in industry, while private practice neurologists considering entering the clinical trial space will benefit from lessons learned by ASENT leadership. The Annual Meeting features career development sessions that offer strategies for achieving professional success in the field of neurotherapeutics. 


    Upcoming events

    • 2025 Late Breaking Abstract Submissions

      • January 02, 2025
      • January 24, 2025
      • 11:59 PM
      • Hyatt Regency Bethesda, Bethesda MD
      Register

      Submitting an Abstract to ASENT

      EXTENDED DEADLINE: Jan 24, 2025 11:59PM ET

      The Abstract Review Committee is committed to presenting the best in neurotherapeutic research at the ASENT Annual Meeting.

      Abstracts selected for presentation by our esteemed review committee will be presented as either a poster or a pipeline presentation at the ASENT 2025 Annual Meeting which will take place at the Hyatt Regency Bethesda in Bethesda, MD, March 12-14, 2025. 

      All abstracts selected for presentation will be listed in the program and will be published in the society's high impact journal Neurotherapeutics, which is published by Elsevier and led by Editor in Chief, M. Maral Mouradian, MD. 

      The abstract should describe original research broadly relevant to the goal of ASENT, which is to encourage and advance the development of improved therapies for diseases and disorders of the nervous system. Please check your abstract carefully for typographical errors, misspellings, etc. Be sure to include data results.

      All abstracts are evaluated by experts in Neurotherapeutics according to the following criteria and overall merit: 

      1. Scientific or clinical impact
      2. Quality of data, analysis, and presentation
      3. Relevance to the discovery and/or development of neurotherapeutics and inclusion of novel targets or new initiatives.
      4. Abstracts must be submitted, presented, and cited in English.

      Upon registering and paying the abstract fee, you will be sent a confirmation email with a link to the Abstract Submission System. If you have not used our partner, Oxford Abstracts, you will be asked to create an account. This will allow you to edit your submission as needed.

      Below you will find details regarding Posters, Pipeline, Guidelines, Eligibility and the benefits of submitting.

      GUIDELINES

      Title: Sentence Case (Max 50 Words)
      Abstract Body: One Paragraph with no subheadings and no tables or graphs (Max 250 Words) Include a sentence on study's purpose, brief description of methods, summary of results, and statement of conclusions reached.
      Authors: Sentence Case

      ELIGIBILITY FAQs 

      - Encore Abstracts, those that have been previously presented at other recent scientific meetings, or submitted for consideration to other scientific meetings, are welcome.

       - International and traditionally underrepresented submissions are welcome.

       - Private, Public and Startup Companies are welcome to submit.

       - Academic researchers and trainees are welcome to submit.

      NOTE: Case studies are NOT considered whereas, Trials in Progress ARE accepted if they can show a novel trial design or new development.

      POSTER PRESENTATIONS
      If your abstract is selected for a poster, you will need to be available to participate in a poster presentation at the annual meeting. This is scheduled to take place on Thursday, March 13 at 5pm.

      PIPELINE PRESENTATIONS
      Submitted abstracts that most closely conform to the above criteria and the ASENT goals may also be selected for a 10-minute oral presentation (including 2 minute Q&A) at one of our Pipeline Presentation sessions. ASENT encourages abstracts from private, public and startup companies and government or academic labs that contain neurotherapeutic research results.

      The ASENT Annual Meeting attracts leaders in neurotherapeutics from all over the world, in all disease states. Pipeline presentations increase exposure to strategic partners in life sciences who have supported novel approaches through partnerships or strategic investments.  

      Past presenters have reported the following results:

      • increase in stock values in the days following the presentation
      • financially beneficial partnerships as a result of presentation
      • development of new companies as a result of participation in meeting

      For questions regarding abstracts, please email jessica@asent.org.

      Show details

    • 2025 Clinical Trial Course

      • March 10, 2025
      • 7:30 AM
      • March 11, 2025
      • 7:30 PM
      • Hyatt Regency Bethesda
      Register

      About This Training Program

      ASENT is pleased to offer a 2-day course March 10-11, 2025 at the Hyatt Regency Bethesda, in Bethesda, MD to introduce clinicians interested in clinical research to the principles of neurotherapeutic clinical trial development and implementation. The course will be especially relevant if you are a neurologist with clinical experience interested in conducting neurotherapeutic clinical trials.

      The course covers the principles of clinical trials from pre-clinical programs to Phase III design and implementation, including necessary regulatory conversations and IND enabling studies, IRB oversight and adverse event tracking and reporting. The course considers clinical trials in the neurotherapeutic space for both drugs and devices. The faculty will also address the unique challenges inherent in developing treatments for nervous system disorders. 


      Show details

    • ASENT 2025 Annual Meeting

      • March 12, 2025
      • 8:00 AM
      • March 14, 2025
      • 1:00 PM
      • Hyatt Regency Bethesda, Bethesda, MD
      Register

      ABOUT ASENT 2025 Annual Meeting

      The ASENT 2025 Annual Meeting, which will take place March 12 - 14, 2025 at the Hyatt Regency Bethesda in Bethesda, MD, is the premier neuroscience and neurotherapeutics conference where senior leaders from leading payers, providers, employers, investors, fast-growing startups, pharma, policymakers, funders and innovation centers gather with one central focus, improving the process of bringing neurotherapeutics to market.

      The plenary sessions, panel discussions, outstanding pipeline presentations and poster sessions focus on the latest science in neurotherapeutics. The conference content will focus on the latest science in neurotherapeutics including innovations across disease states, novel delivery systems, gene therapy and biomarkers, and of course the latest drug therapies and devices. The event features plenary sessions, panel discussions, satellite luncheons, networking meetings, pipeline presentations and poster sessions.

      WHO ATTENDS

      Physician-Scientists | Neurologists | Neuroscientists | Trainees | Drug and Device Companies | CROs | Fellows | Post-docs | Founders | Funders | Industry Leaders | Nonprofit Organizations and Advocacy Groups | Journal Editors | Representatives from NIH, NIA, NIDA, NINDS and FDA


      Show details
    Powered by Wild Apricot Membership Software